In connection with convertible bond issues during the period July 2018 – January 2019, Redwood Pharma issued 287,958 warrants expiring on various occasions during 2021 and the beginning of 2022. After recalculation due to the rights issue in September 2019, the warrants entitle the holder to subscribe for a total of 293,716 shares.
The holder of the warrants has today used all of these to subscribe for new shares. Redwood Pharma will thus receive approximately SEK 2.1 million.
The subscription increases the number of shares in Redwood Pharma by 293,716 from 14,698,693 to 14,992,409. The share capital increases by SEK 58,743.20 from SEK 2,939,738.60 to SEK 2,998,481.80.
For more information:
Martin Vidaeus, CEO Redwood Pharma AB (publ.)
Tel: +46 (0) 70 232 29 29
This information is information that Redwood Pharma AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, on May 18, 2020.
About Redwood Pharma
Redwood Pharma develops ophthalmic products for unmet medical needs. The Company’s first project is the development of drug candidate RP101 with a known active substance against chronic dry eye in postmenopausal women who have moderate to severe symptoms. With the drug delivery platform IntelliGel the release of active substances is controlled. Through the use of IntelliGel, Redwood Pharma can also improve dosing of other established drugs. Redwood Pharma’s strength lies in formulation and early clinical development. Revenues will be generated through licensing agreements with pharmaceutical companies that have capabilities to manufacture and sell commercial products worldwide.
Redwood Pharma AB (publ.) is listed on the Spotlight Stock Market (Ticker: REDW.ST, ISIN: SE008294789).
For more information visit: www.redwoodpharma.com